A GLP-1 receptor agonist is a compound that activates the receptor for the incretin hormone GLP-1, mimicking its natural signalling. Understanding the two words — GLP-1 and agonist — explains the whole class.

In plain terms: it borrows one of the body's own "I'm full, release insulin" signals and makes it last far longer than nature does.

TirzepatideGIP receptorstronger engagementGLP-1 receptorweaker engagement
Fig. Tirzepatide is a single 39-residue peptide that activates two incretin receptors — GIP and GLP-1 — via one molecule (a dual agonist). Receptor-pharmacology analyses describe it as imbalanced, engaging the GIP receptor more than GLP-1. Semaglutide, by contrast, activates GLP-1 alone.

What GLP-1 is

GLP-1 (glucagon-like peptide-1) is an incretin — a gut hormone released in response to food that participates in glucose regulation and satiety signalling1. It tells the body to release insulin, slow stomach emptying, and feel full sooner. It is part of the body's own post-meal signalling system.

What "agonist" means

An agonist is a molecule that binds a receptor and activates it — as opposed to an antagonist, which blocks it. So a GLP-1 receptor agonist switches on the same receptor GLP-1 does.

The engineering problem

Native GLP-1 has a half-life of minutes — it is degraded almost instantly by the enzyme DPP-41. To be useful as a medication, the agonists are engineered to resist that breakdown, most notably with a fatty-acid chain that binds albumin and stretches the half-life to about a week2.

The family

Each step adds a receptor to the same incretin foundation.

What the human trials found

Unlike most peptides on this site, this class has a large, rigorous human evidence base:

Trial (cited)PeopleKey resultYear
STEP 131,961 adults with obesity, no diabetesSemaglutide: ~14.9% average body-weight loss over 68 weeks2021
SURMOUNT-142,539 adults with obesity, no diabetesTirzepatide: up to ~20.9% average loss over 72 weeks (top dose)2022

In plain terms: single- and dual-agonist versions of this class produced roughly 15% and up to 21% average weight loss in large human trials — results that reshaped the field.

The core peer comparison is semaglutide vs tirzepatide.

This is an educational overview of a drug class, not medical advice or a judgement about any individual's treatment.